- Open
- 1.18
- High
- 1.25
- Low
- 1.16
- Close
- 1.19
- Change
- -0.03 (-2.13%)
- Volume
- 3,231,318
⌘K
| 15 Apr 2026 | 12:16:03 | Holding(s) in Company |
| 14 Apr 2026 | 14:09:51 | Holding(s) in Company |
| 26 Feb 2026 | 15:30:33 | Holding(s) in Company |
| 24 Feb 2026 | 14:28:58 | Holding(s) in Company |
| 12 Feb 2026 | 16:07:12 | Holding(s) in Company |
| 10 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 8 Jul 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 10 Jul 2023 | Annual Report and Accounts (to 2022-12-31) |
GENinCode is a company that focuses on assessing the risk of cardiovascular disease, which is the primary cause of death and disability globally. Their products utilize a combination of genetic and clinical data to provide healthcare professionals with advanced clinical information for patient risk assessment.
| 15 Apr 2026 | 12:16:03 | Holding(s) in Company |
| 14 Apr 2026 | 14:09:51 | Holding(s) in Company |
| 26 Feb 2026 | 15:30:33 | Holding(s) in Company |
| 24 Feb 2026 | 14:28:58 | Holding(s) in Company |
| 12 Feb 2026 | 16:07:12 | Holding(s) in Company |
| 10 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 8 Jul 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 10 Jul 2023 | Annual Report and Accounts (to 2022-12-31) |
GENinCode is a company that focuses on assessing the risk of cardiovascular disease, which is the primary cause of death and disability globally. Their products utilize a combination of genetic and clinical data to provide healthcare professionals with advanced clinical information for patient risk assessment.